ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

MMRVNS vaccine

Its studies are mostly in Measles, led by GlaxoSmithKline.

Furthest: phase 3, since Jul 29, 20261 company-led study, 1 open or runningNext primary completion: Jun 27, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 3since Jul 29, 2026Jul 29, 2026Jun 27, 2028phase 3 · NCT07742644

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 29, 2026First study: phase 3 study in MeaslesFirst studyNCT07742644 · 1,860 planned · United States, Argentina, Finland and more

Ahead

  1. Jun 27, 2028Primary completion: phase 3 study in MeaslesNCT07742644

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“MMRVNS vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07742644Measles · United States, Argentina, Finland and more3Not yet recruitingJun 27, 20281,860

How it is read

Names in the registry

  • “MMRVNS vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.